Economic models in type 2 diabetes

References

• Nixon J, Stoykova B, Glanville J, et al. The UK NHS economic evaluation database: economic issues in evaluations of health technology. Int J Technol Assess Health Care 2000;16:731-42
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
   Google Scholar
• Campbell IW. Epidemiology and clinical presentation of type 2 diabetes. Value Health 2000;3:S3-6
   PubMedGoogle Scholar
• The Mount Hood 4 Modelling Group. Computer modelling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46
   PubMed Web of Science ®Google Scholar
• Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. PharmacoEconomics 2006;355-71
   PubMed Web of Science ®Google Scholar
• Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001;44:2140-55
   PubMed Web of Science ®Google Scholar
• Brandle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model inpatients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Therapeut 2007;45:203-20
   PubMed Web of Science ®Google Scholar
• Brown JB, Russell A, Chan W, et al. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000;50(Suppl. 3):S15-46
   PubMedGoogle Scholar
• Chen J, Alemao E, Yin D, et al. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab 2008;10(Suppl. 1):33-42
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study UKPDS Outcomes Model (UKPDS no 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725-34
   PubMed Web of Science ®Google Scholar
• Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM II Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093-101
   PubMed Web of Science ®Google Scholar
• Mueller E, Maxion-Bergemann S, Gultyaev D, et al. Development and validation of the economic assessment of glycemic control and long-term effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219-36
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Brandt A, Gozzoli V, et al. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000;50(Suppl. 3):S47-56
   PubMedGoogle Scholar
• Palmer AJ, Roze S, Valentine W, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus types 1 and 2 to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl. 1):S5-26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type 1 diabetes: a Swiss perspective. Diabetologia 2000;43:13-26
   PubMed Web of Science ®Google Scholar
• Tilden D, Mariz S, Bryan T, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics 2007;25:39-54
   PubMed Web of Science ®Google Scholar
• Xie X, Vondeling H. Cost–utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value Health 2008;11(Suppl):S23-32
   PubMedGoogle Scholar
• Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmaco Economics 2007;25:253-66
   PubMed Web of Science ®Google Scholar
• Brown RR. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. Am J Health Syst Pharm 1998;55(Suppl. 4):S24-27
   PubMedGoogle Scholar
• Ramsdell JW, Grossman JA, Stephens JM, et al. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose. Am J Manag Care 1999;5:1007-24
   PubMed Web of Science ®Google Scholar
• Ramsdell JW, Braunstein SN, Stephens JM, et al. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. PharmacoEconomics 2003;21:819-37
   PubMed Web of Science ®Google Scholar
• Nicklasson L, Palmer AJ, Roze S. Simulating the long term cost-effectiveness of a combination regimen of repaglinide plus rosiglitazone vs. rosiglitazone monotherapy over a 30-year period. Value in Health 2003;6:334
   Google Scholar
• Nicklasson L, Palmer AJ, Gall M, et al. Estimating the cost-effectiveness of repaglinide plus metformin vs. nataglinide plus metformin. Value in Health 2003;6:333-4
   Google Scholar
• Fon F, Celaya J, Ayala C, et al. A pharmacoeconomic evaluation for diabetes type 2 (DM 2) patients with inihibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) as add-on therapy. Value in Health 2007;10:A254
   Google Scholar
• Celaya J, Fon F, Ayala C, et al. A pharmacoeconomic evaluation for diabetes type 2 (DM 2) with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) in monotherapy. Value in Health 2007;10:A254
   Google Scholar
• NICE. Management of type 2 diabetes management of blood glucose. Inherited Clinical Guideline G. 2002
   Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. Br Med J 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. Br Med J 2000;321:412-19
   PubMed Web of Science ®Google Scholar
• Coyle D, Lee KM, O’Brien BJ. The role of models within economic analysis: focus on type 2 diabetes mellitus. PharmacoEconomics 2002;20(Suppl. 1):11-19
   PubMedGoogle Scholar
• Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. PharmacoEconomics 2002;20(Suppl. 1):S43-53
   PubMedGoogle Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl. 1):S27-40
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweizerische Medizinische Wochenschrift 2000;130:1034-40
   PubMedGoogle Scholar
• Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health 2008;11(Suppl. 1):S43-51
   PubMedGoogle Scholar
• Coyle D, Palmer A, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmaco Economics 2002;20(Suppl. 1): S31-42
   PubMedGoogle Scholar
• Goodall G, Jendle JH, Valentine WJ, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: Modelling the long-term health economic implications in a Swedish setting. Int J Clin Pract 2008;62:869-76
   Google Scholar
• Minshall M, Oglesby A, Wintle M, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22-33
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with Type 2 diabetes: a projection using the CORE diabetes model. Curr Med Res Opin 2004;20(Suppl. 1):S59-66
   PubMedGoogle Scholar
• Palmer AJ. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Curr Med Res Opin 2004;20:S41-51
   PubMed Web of Science ®Google Scholar
• Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metabol 2007;9:103-13
   PubMed Web of Science ®Google Scholar
• Ray J, Boye K, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22
   PubMed Web of Science ®Google Scholar
• Ray J, Huet D, Valentine W, et al. Long-term costs and clinical outcomes associated with metformin–glibenclamide combination tablets (Glucovance«) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting. Br J Diabetes Vasc Dis 2008;8:39-44
   Google Scholar
• Roze S, Valentine WJ, Evers T, et al. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Curr Med Res Opin 2006;22:1415-24
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005;21:2063-71
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabetic Med 2007;24:982-1002
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with Type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther 2007;24:273-90
   PubMed Web of Science ®Google Scholar
• Shaya FT. Clinical and economic evaluation of exenatide for formulary decisions. J Med Econ 2007;10:529-37
   Google Scholar
• Neeser K. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. PharmacoEconomics 2004;22:321-41
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost–utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Gray AM, Clarke P. The economic analyses of the UK prospective diabetes study. Diabet Med 2008;25(Suppl. 2):S47-51
   PubMedGoogle Scholar
• NICE. Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine: Technology Appraisal No.53. 2002
   Google Scholar
• NICE. Type II diabetes: the management of type II diabetes (NICE clinical guideline 66). 2008
   Google Scholar
• NICE. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. 2008
   Google Scholar
• Schwarz B, Gouveia M, Chen J, et al. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metabol 2008;10(Suppl. 1):43-55
   PubMed Web of Science ®Google Scholar
• National Coordinating Centre for Health Technology Assessment. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Tech Assess 2007;11;140
   Web of Science ®Google Scholar
• Bagust A, Evans M, Beale S, et al. A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. PharmacoEconomics 2006;24(Suppl. 1):5-19
   PubMedGoogle Scholar
• Beale S, Bagust A, Shearer AT, et al. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. PharmacoEconomics 2006;24(Suppl. 1):S21-34
   PubMedGoogle Scholar
• Shearer AT, Bagust A, Liebl A, et al. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany. PharmacoEconomics 2006;24(Suppl. 1):S35-48
   PubMedGoogle Scholar
• Shearer A, Bagust A, Ampudia B, et al. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. PharmacoEconomics 2006;24(Suppl. 1):S49-59
   PubMedGoogle Scholar
• Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of Type 2 diabetes. Clin Ther 2000;22:116-27
   PubMed Web of Science ®Google Scholar
• Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2002;24:1690-705
   PubMed Web of Science ®Google Scholar
• Ward AJ, Salas M, Caro JJ, et al. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Eff Resour Allocat 2004;2:2
   PubMedGoogle Scholar
• Eddy D. Bringing health economic modelling to the 21st century. Value Health 2006;9:168-73
   PubMed Web of Science ®Google Scholar
• Diabetes PhD and Archimedes, 2010. Available at: http://www.diabetesarchive.net/diabetesphd/archimedes.jsp [Last accessed 27 May 2010]
   Google Scholar
• Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64
   PubMed Web of Science ®Google Scholar
• Lewis V, Kloer P, Prasad N, et al. The HOPE study and diabetes Heart Outcomes Prevention Evaluation. Lancet 2000;355:1182
   PubMedGoogle Scholar
• The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Framingham Heart Study, 2009. Available at: http://framingham.com/heart/backgrnd.htm [Last accessed 27 May 2010]
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B.E, Moss SE, et al. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol 1984;119:54-61
   PubMed Web of Science ®Google Scholar
• Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
   PubMed Web of Science ®Google Scholar
• Boutayeb A, Chetouani A. A critical review of mathematical models and data used in diabetology. BioMedical Engineering OnLine 2006;5:43
   PubMed Web of Science ®Google Scholar
• NICE. Guidance on the use of glitazones for the treatment of type 2 diabetes, 2003
   Google Scholar
• Warren E, Weatherley J, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Tech Assess 2004;8:25-35
   Web of Science ®Google Scholar
• Scottish Medicines Consortium. Sitagliptin 100 mg tablets (Januvia®) Merck, Sharpe & Dohme Limited. No. (408/07). 7 September 2007
   Google Scholar
• Tarride JE, Hopkins R, Blackhouse G, et al. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. PharmacoEconomics 2010;28:255-77
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods For The Economic Evaluation Of Health Care Programmes, 3rd Oxford Medical Publications, 2005
   Google Scholar
• NICE. Guide to the methods of technology appraisal, June 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Last accessed 27 May 2010]
   Google Scholar
• NICE. Guide to the multiple technology appraisal process, October 2009. Available at: http://www.nice.org.uk/media/916/6B/Guide_to_the_MTA-proof_8-26-10-09.pdf [Last accessed 27 May 2010]
   Google Scholar